Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab-gcpt) for Treatment of Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic...
Takeda Announces U.S. FDA Approval of Gammagard Liquid ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 30, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration...
FDA Approves Gamifant (emapalumab-lzsg) as First-Ever Treatment for Adults and Children with Macrophage Activation Syndrome in Still's Disease
Sobi today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for the treatment of adult and pediatric...
Health Care Expenditure Expected to Top GDP Growth 2024 to 2033
The annual growth in national health spending is expected to be faster than average gross domestic product (GDP) growth during 2024 to 2033, according...
Weight Loss Continues Five Years After Tummy Tucks
Patients undergoing abdominoplasty experience continued weight loss up to five years postoperatively, according to a study published in the July issue...
Considerable Variation Seen in Commercial Pricing for Surgery Services
Commercial pricing varies considerably for general surgery services, with facility prices exhibiting greater variability, according to a research letter...
Measles Outbreak in Kentucky Confirmed
There has been nationwide total of 1,267 confirmed cases of measles this year, with Kentucky being the latest state to announce an outbreak, the U.S. Centers...
Greater Neighborhood Disadvantage Tied to Inflammatory, Alzheimer Disease Biomarkers
Greater neighborhood disadvantage is associated with increased inflammatory and Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in older adults,...
Hearing Aids Are a Boon To Social Life, Study Finds
THURSDAY, July 3, 2025 — Some folks won’t use hearing aids because they’re worried the devices will make them look old or get in the...
High Levels of Particulate Matter Found Near Electric Vehicle Charging Stations in L.A.
THURSDAY, July 3, 2025 — Electric cars are increasingly common due to their potential environmental benefits, but a new study suggests that high...
Prevent 4th of July Firework Injuries by Taking These Simple Steps
THURSDAY, July 3, 2025 — Fireworks are the pinnacle of many Fourth of July celebrations, and while they can be festive and fun, they can also land...
Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma
Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug...
Monthly News Roundup - June 2025
Dupixent Approved in the U.S. as the First Targeted Medicine to Treat Patients with Bullous Pemphigoid Dupixent (dupilumab) has been approved for the...
FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger Than 6 Years Taking Extended-Release Stimulants for ADHD
FDA Drug Safety Communication - June 30, 2025 What safety concern is FDA announcing?The U.S. Food and Drug Administration (FDA) is revising the labeling...
Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-line Gastric Cancer
THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial...
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Cefazolin for Injection Due to Product Mispackaging
Sandoz, Inc. (“Sandoz”) is initiating a voluntary recall of one (1) lot of Cefazolin for Injection, USP, 1 gram per vial. This single...
Body Fat Analysis, Waist Size Better Than BMI For Assessing Health
FRIDAY, June 27, 2025 — A person’s body fat percentage provides a better estimate of their risk for early death than their body mass index...
Recently Added
Recently added consumer and prescribing information: Lynozyfic, Arynta, Harliku, Ibtrozi, Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Lynozyfic Lynozyfic (linvoseltamab-gcpt) is a bispecific B-cell maturation antigen (BCMA)‑directed CD3 T-cell engager for the treatment of relapsed o...
- Harliku Harliku (nitisinone) is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated for the reduction of urine homogentisic acid in adult...
- Yeztugo Yeztugo (lenacapavir) is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor for pre‑exposure prophylaxis (PrEP) to reduce the r...